{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:44:39Z","timestamp":1771476279214,"version":"3.50.1"},"reference-count":31,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with Gaucher disease (GD), a rare autosomal recessive glycosphingolipid storage disease, commonly present to hematologists with unexplained splenomegaly, thrombocytopenia, anemia, and bone symptoms. Patients with GD may develop other manifestations, such as autoimmune thrombocytopenia, monoclonal gammopathy, multiple myeloma, or, even more rarely, other hematological malignancies; sometimes they are first diagnosed during an assessment of those disorders. Although the diagnosis and management of patients with GD have significantly evolved over the last 30 years, some patients remain poor responders to GD-specific therapy, needing novel and investigational therapies. Ideally, patients with GD, like patients with other rare diseases, should be managed by a multidisciplinary team expert with the diverse clinical manifestations and potential GD-related or -unrelated comorbidities. The hematology community should be knowledgeable regarding the presentation and the variety of hematologic complications and comorbidities associated with Gaucher disease.<\/jats:p>","DOI":"10.1182\/hematology.2020000123","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T03:16:15Z","timestamp":1607138175000},"page":"389-394","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact"],"prefix":"10.1182","volume":"2020","author":[{"given":"Ari","family":"Zimran","sequence":"first","affiliation":[{"name":"Gaucher Unit,"},{"name":"School of Medicine, Hebrew University, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Ruchlemer","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shaare Zedek Medical Center, and"},{"name":"School of Medicine, Hebrew University, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoshana","family":"Revel-Vilk","sequence":"additional","affiliation":[{"name":"Gaucher Unit,"},{"name":"School of Medicine, Hebrew University, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020121621171790800_B1","first-page":"1121","article-title":"Gaucher disease and related lysosomal storage diseases","volume-title":"Williams Hematology","author":"Zimran","year":"2016","edition":"9th ed"},{"issue":"3","key":"2020121621171790800_B2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ymgme.2017.08.002","article-title":"Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians","volume":"122","author":"Mehta","year":"2017","journal-title":"Mol Genet Metab"},{"issue":"10","key":"2020121621171790800_B3","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3390\/jcm8101662","article-title":"Long term follow-up of 103 untreated adult patients with type 1 Gaucher disease","volume":"8","author":"Dinur","year":"2019","journal-title":"J Clin Med"},{"issue":"1","key":"2020121621171790800_B4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/(SICI)1096-8652(199705)55:1<28::AID-AJH5>3.0.CO;2-5","article-title":"Abdominal ultrasound findings mimicking hematological malignancies in a study of 218 Gaucher patients","volume":"55","author":"Neudorfer","year":"1997","journal-title":"Am J Hematol"},{"issue":"6","key":"2020121621171790800_B5","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s10545-008-0868-z","article-title":"Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry","volume":"31","author":"Fairley","year":"2008","journal-title":"J Inherit Metab Dis"},{"issue":"9","key":"2020121621171790800_B6","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","article-title":"Differential effects of severe vs mild GBA mutations on Parkinson disease","volume":"84","author":"Gan-Or","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"2020121621171790800_B7","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00415-020-09705-7","article-title":"Precision medicine in Parkinson\u2019s disease: emerging treatments for genetic Parkinson\u2019s disease","volume":"267","author":"Schneider","year":"2020","journal-title":"J Neurol"},{"issue":"2","key":"2020121621171790800_B8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/mds.27903","article-title":"Substrate reduction therapy for GBA1-associated parkinsonism: are we betting on the wrong mouse?","volume":"35","author":"Sidransky","year":"2020","journal-title":"Mov Disord"},{"issue":"7","key":"2020121621171790800_B9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/qjmed\/91.7.483","article-title":"Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease","volume":"91","author":"Elstein","year":"1998","journal-title":"QJM"},{"issue":"9214","key":"2020121621171790800_B10","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher\u2019s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"2020121621171790800_B11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/bjh.15402","article-title":"How we manage Gaucher Disease in the era of choices","volume":"182","author":"Revel-Vilk","year":"2018","journal-title":"Br J Haematol"},{"key":"2020121621171790800_B12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bcmd.2017.09.003","article-title":"Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy","volume":"68","author":"Zimran","year":"2018","journal-title":"Blood Cells Mol Dis"},{"issue":"6","key":"2020121621171790800_B13","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10545-010-9175-6","article-title":"Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy","volume":"33","author":"Stein","year":"2010","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"2020121621171790800_B14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/SLE.0000000000000518","article-title":"Splenectomy in Gaucher disease: a call for minimally invasive surgery","volume":"28","author":"Freund","year":"2018","journal-title":"Surg Laparosc Endosc Percutan Tech"},{"issue":"4","key":"2020121621171790800_B15","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3390\/ijms21041247","article-title":"Immunoglobulin abnormalities in Gaucher disease: an analysis of 278 patients included in the French Gaucher Disease Registry","volume":"21","author":"Nguyen","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"22","key":"2020121621171790800_B16","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1182\/blood-2018-02-834689","article-title":"MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association","volume":"131","author":"Weinreb","year":"2018","journal-title":"Blood"},{"key":"2020121621171790800_B17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bcmd.2016.12.006","article-title":"Classifying the additional morbidities of Gaucher disease","volume":"68","author":"Langeveld","year":"2018","journal-title":"Blood Cells Mol Dis"},{"key":"2020121621171790800_B18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bcmd.2016.10.008","article-title":"Management goals for type 1 Gaucher disease: an expert consensus document from the European Working Group on Gaucher Disease","volume":"68","author":"Biegstraaten","year":"2018","journal-title":"Blood Cells Mol Dis"},{"issue":"12","key":"2020121621171790800_B19","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2004-12-4672","article-title":"Gaucher disease and cancer incidence: a study from the Gaucher Registry","volume":"105","author":"Rosenbloom","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2020121621171790800_B20","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa1508808","article-title":"Clonal immunoglobulin against lysolipids in the origin of myeloma","volume":"374","author":"Nair","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2020121621171790800_B21","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/bjh.15659","article-title":"Saposin C is a frequent target of paraproteins in Gaucher disease-associated MGUS\/multiple myeloma","volume":"184","author":"Preuss","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"2020121621171790800_B22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4452","article-title":"Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy","volume":"235","author":"Pavlova","year":"2015","journal-title":"J Pathol"},{"key":"2020121621171790800_B23","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3389\/fimmu.2019.01143","article-title":"\u03b2-Glycosphingolipids as mediators of both inflammation and immune tolerance: a manifestation of randomness in biological systems","volume":"10","author":"Ilan","year":"2019","journal-title":"Front Immunol"},{"key":"2020121621171790800_B24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13023-019-1085-6","article-title":"Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1","volume":"14","author":"Peterschmitt","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"2020121621171790800_B25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13023-018-0810-x","article-title":"Patient reported outcome measures in rare diseases: a narrative review","volume":"13","author":"Slade","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"2020121621171790800_B26","article-title":"Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease","author":"Dinur","year":"","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2020121621171790800_B27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bcmd.2012.10.007","article-title":"Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase","volume":"50","author":"Bendikov-Bar","year":"2013","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"2020121621171790800_B28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcmd.2012.09.006","article-title":"Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease","volume":"50","author":"Zimran","year":"2013","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"2020121621171790800_B29","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"2020121621171790800_B30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ebiom.2018.11.037","article-title":"The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase","volume":"38","author":"Fog","year":"2018","journal-title":"EBioMedicine"},{"key":"2020121621171790800_B31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13023-018-0903-6","article-title":"A health state utility valuation study to assess the impact of treatment mode of administration in Gaucher disease","volume":"13","author":"Hadi","year":"2018","journal-title":"Orphanet J Rare Dis"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/389\/1795030\/hem2020000123c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/389\/1795030\/hem2020000123c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T17:36:58Z","timestamp":1618594618000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/389\/474359\/A-patient-with-Gaucher-disease-and-plasma-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000123","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}